Flu antibody therapy from South Korea's Celltrion advancing in PhII


South Korean biopharma Celltrion says it is on the path to come up with the first antibody therapy to treat the flu as CT-P27 moves through Phase II clinical trials. Expectations are such that a successful outcome could bring a U.S. FDA breakthrough therapy designation.

The Korea Herald, citing the CEO and founder Seo Jung-jin, said preparations for the second part of Phase II trials are underway, though a location remains undetermined after the first part of the trial took place in London earlier this year.

“Given the possibility that the drug may receive ‘breakthrough therapy’ designation, we are looking at potential countries in which we can conditionally commercialize the drug without conducting phase-III trials (as protocol dictates),” Celltrion spokesman Lee Kun-hyuk told the Korea Herald.


Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

The Celltrion candidate faces competition from the Genentech unit of Roche ($RHBBY), which is also at work on two antibody therapies along the same lines. But Celltrion, citing success in its development of biosimilars, said it is confident.

“As we have been a ‘first-mover’ in biosimilars, we hope that we can reap similar success in the new drug development arena as well,” Lee told the Korea Herald.

Celltrion hopes that its biosimilar of Remicade makes it on sales in the U.S. this year, despite a legal challenge Johnson & Johnson ($JNJ). Pfizer ($PFE) owns the U.S. rights to the copycat biologic by virtue of its purchase of Hospira last year--which in turn has a marketing pact with South Korea's Celltrion. The biosimilar dubbed Inflectra (infliximab-dyyb), has been sold in Europe since 2015.

- here's the story from the Korea Herald

Related Articles:
Novartis CEO eyes biosimilar plays in Asia that fit with Sandoz plans


Suggested Articles

That didn’t take long. Sanofi CEO Paul Hudson has only been at the reins for a couple months, but on Tuesday, he unveiled a major shakeup.  

New "gold standard" data could further increase doctors' confidence in multiple myeloma med Darzalex, Johnson & Johnson says.

Could Monday's cancer buyout be a hint about what Sanofi CEO Paul Hudson will unveil at Tuesday's investor confab? Analysts think so.